.. .. Toxicité-hépatique,

.. .. Les-situations-d'échec-virologique,

. , L'importance des recherches de mutation de résistance, p.61

C. .. ,

B. .. ,

, Références bibliographiques

V. Découvertes-de-séropositivité and . De-sida, Point épidémiologique du 23 mars 2017. / Actualités / Infection à VIH et sida / VIH-sida / IST / Maladies infectieuses / Dossiers thématiques, 2017.

M. May, M. Gompels, V. Delpech, K. Porter, F. Post et al., Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study, BMJ, vol.343, p.6016, 2011.

S. Nozza, V. Svicher, A. Saracino, G. Ettorre, D. Luca et al., State of the Art of Dual Therapy in 2015, AIDS Rev, vol.17, pp.127-161, 2015.

A. F. Capetti, G. Sterrantino, M. V. Cossu, G. Orofino, G. Barbarini et al., Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort, PloS One, vol.11, 2016.

P. Gantner, L. Cuzin, C. Allavena, A. Cabie, P. Pugliese et al., Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study, HIV Med, vol.18, pp.704-712, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01906302

P. Girard, J. Llibre, C. Hung, C. Brinson, F. Castelli et al., Études SWORD 1 et 2 de phase III : le switch vers une stratégie 2DR de DTG/RPV maintient la suppression virologique pendant 48 semaines, Médecine Mal Infect, vol.47, p.142, 2017.

C. Gubavu, T. Prazuck, M. Niang, J. Buret, C. Mille et al., Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, 2016.

P. Cahn, M. J. Rolón, M. I. Figueroa, A. Gun, P. Patterson et al., Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study, J Int AIDS Soc, vol.20, pp.1-7, 2017.

D. Sculier, A. Gayet-ageron, M. Battegay, M. Cavassini, J. Fehr et al., Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study, BMC Infect Dis, vol.17, 2017.

O. Vih/sida-n.d, , 2017.

V. Découvertes-de-séropositivité and . De-sida, Point épidémiologique du 23 mars 2017. / Actualités / Infection à VIH et sida / VIH-sida / IST / Maladies infectieuses / Dossiers thématiques, 2017.

J. Plantier, M. Leoz, J. E. Dickerson, D. Oliveira, F. Cordonnier et al., A new human immunodeficiency virus derived from gorillas, Nat Med, vol.15, pp.871-873, 2009.

R. Thiébaut, S. Matheron, A. Taieb, F. Brun-vezinet, G. Chêne et al., Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort, AIDS Lond Engl, vol.25, pp.865-872, 2011.

J. Drylewicz, S. Matheron, L. E. Damond, F. Bonnet, F. Simon et al., Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France, AIDS Lond Engl, vol.22, pp.457-68, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00258131

S. Saayman, S. A. Ali, K. V. Morris, and M. S. Weinberg, The therapeutic application of CRISPR/Cas9 technologies for HIV, Expert Opin Biol Ther, vol.15, pp.819-849, 2015.

K. Barton, A. Winckelmann, and S. Palmer, HIV-1 Reservoirs During Suppressive Therapy, Trends Microbiol, vol.24, pp.345-55, 2016.

T. Chun, S. Moir, and A. S. Fauci, HIV reservoirs as obstacles and opportunities for an HIV cure, Nat Immunol, vol.16, pp.584-593, 2015.

J. Couturier, J. W. Suliburk, J. M. Brown, D. J. Luke, N. Agarwal et al., Human adipose tissue as a reservoir for memory CD4+ T cells and HIV, AIDS Lond Engl, vol.29, pp.667-74, 2015.

S. Pallikkuth, M. Sharkey, D. Z. Babic, S. Gupta, G. W. Stone et al., Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy, J Virol, vol.90, pp.2718-2746, 2015.

R. Tressler and C. Godfrey, NRTI backbone in HIV treatment: will it remain relevant?, Drugs, vol.72, pp.2051-62, 2012.

A. Calcagno, J. Cusato, L. Marinaro, L. Trentini, C. Alcantarini et al., Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines, Pharmacogenomics J, vol.16, pp.514-522, 2016.

A. K. Gibson, B. M. Shah, P. H. Nambiar, J. J. Schafer, and . Tenofovir-alafenamide, Ann Pharmacother, vol.50, pp.942-52, 2016.

P. Zhan, X. Chen, D. Li, Z. Fang, D. Clercq et al., HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design, Med Res Rev, vol.33, issue.1, pp.1-72, 2013.

L. Huang, S. A. Wring, J. L. Woolley, K. R. Brouwer, C. Serabjit-singh et al., Induction of PGlycoprotein and Cytochrome P450 3A by HIV Protease Inhibitors, Drug Metab Dispos, vol.29, pp.754-60, 2001.

L. L. Von-moltke, D. J. Greenblatt, J. M. Grassi, B. W. Granda, S. X. Duan et al., Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir, J Clin Pharmacol, vol.38, pp.106-117, 1998.

A. Carr, K. Samaras, D. J. Chisholm, and D. A. Cooper, Pathogenesis of HIV-1-protease inhibitorassociated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance, The Lancet, vol.351, pp.3391-3392, 1998.

B. Rodés, J. Sheldon, C. Toro, V. Jiménez, M. Á. Álvarez et al., Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy, J Antimicrob Chemother, vol.57, pp.709-722, 2006.

D. Desbois, B. Roquebert, G. Peytavin, F. Damond, C. G. Bénard et al., In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors, Antimicrob Agents Chemother, vol.52, pp.1545-1553, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00263591

Y. Goldgur, R. Craigie, G. H. Cohen, T. Fujiwara, T. Yoshinaga et al., Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design, Proc Natl Acad Sci, vol.96, pp.13040-13043, 1999.

J. L. Adams, B. N. Greener, and A. Kashuba, Pharmacology of HIV integrase inhibitors, Curr Opin HIV AIDS, vol.7, pp.390-400, 2012.

T. M. Dando, C. M. Perry, and . Enfuvirtide, Drugs, vol.63, pp.2767-2768, 2003.

V. Joly, K. Jidar, M. Tatay, and P. Yeni, Enfuvirtide: from basic investigations to current clinical use, Expert Opin Pharmacother, vol.11, pp.2701-2714, 2010.

Q. Tan, Y. Zhu, J. Li, Z. Chen, G. W. Han et al., Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex, Science, vol.341, pp.1387-90, 2013.

S. M. Woollard and G. D. Kanmogne, Maraviroc: a review of its use in HIV infection and beyond, Drug Des Devel Ther, vol.9, pp.5447-68, 2015.

, Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial, BREATHER (PENTA 16) Trial Group, vol.3, pp.30054-30060, 2016.

P. De-truchis, Efficacy of a maintenance four-days-a-week regimen: the ANRS1624D trial, 21st International AIDS Conference

. Encore1-study-group, D. Carey, R. Puls, J. Amin, M. Losso et al., Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Lancet Infect Dis, vol.15, pp.793-802, 2015.

J. Moltó, M. Valle, E. Ferrer, P. Domingo, A. Curran et al., Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial, J Antimicrob Chemother, vol.70, pp.1139-1184, 2015.

, Maintenance Therapy With 400/100 mg of Darunavir/Ritonavir for 48 Weeks n, 2017.

F. Pulido, J. R. Arribas, R. Delgado, E. Cabrero, J. González-garcía et al., Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV, AIDS Lond Engl, vol.22, pp.1-9, 2008.

C. Gutmann, A. Cusini, H. F. Günthard, C. Fux, B. Hirschel et al., Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir, AIDS Lond Engl, vol.24, pp.2347-54, 2010.

C. Katlama, M. A. Valantin, M. Algarte-genin, C. Duvivier, S. Lambert-niclot et al., Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136, AIDS Lond Engl, vol.24, pp.2365-74, 2010.

A. Torres-cornejo, O. J. Benmarzouk-hidalgo, A. Gutiérrez-valencia, P. Pérez-romero, R. Martín-peña et al., Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy, AIDS Lond Engl, vol.28, pp.201-209, 2014.

A. Antinori, J. Arribas, J. Fehr, P. Girard, A. Horban et al., The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL, J Int AIDS Soc, vol.17, 2014.

S. Mathis, B. Khanlari, F. Pulido, M. Schechter, E. Negredo et al., Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis, PloS One, vol.6, 2011.

J. Rojas, J. L. Blanco, M. A. Marcos, M. Lonca, A. Tricas et al., Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression, J Antimicrob Chemother, vol.71, pp.1975-81, 2016.

C. Katlama, C. Soulié, F. Caby, A. Denis, C. Blanc et al., Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia, J Antimicrob Chemother, vol.71, pp.2646-50, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01340219

D. Hiv-1 and :. Conference, , 2017.

C. Gubavu, T. Prazuck, M. Niang, J. Buret, C. Mille et al., Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, 2016.

A. C. Achhra, G. Mwasakifwa, J. Amin, and M. A. Boyd, Efficacy and safety of contemporary dualdrug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis, Lancet HIV, vol.3, issue.16, pp.30015-30022, 2016.

R. Landman, C. Capitant, D. Descamps, C. Chazallon, G. Peytavin et al., Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study, J Antimicrob Chemother, vol.64, pp.118-143, 2009.

R. B. Osih, P. Taffé, M. Rickenbach, A. Gayet-ageron, L. Elzi et al., Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study, AIDS Res Hum Retroviruses, vol.26, pp.1239-1285, 2010.

T. Prazuck, D. Zucman, V. Avettand-fènoël, E. Ducasse, D. Bornarel et al., LongTerm HIV-1 Virologic Control in Patients on a Dual NRTI Regimen, HIV Clin Trials, vol.14, pp.120-126, 2013.

P. Cahn, J. Andrade-villanueva, J. R. Arribas, J. M. Gatell, J. R. Lama et al., Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviraltherapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial, Lancet Infect Dis, vol.14, pp.572-80, 2014.

V. Joly and . Maintenance, ANRS 167 LAMIDOL TRIAL | CROI Conference, 2017.

F. Raffi, A. G. Babiker, L. Richert, J. Molina, E. C. George et al., Ritonavirboosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet Lond Engl, vol.384, issue.14, pp.61170-61173, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01108186

L. Curtis, G. Nichols, C. Stainsby, J. Lim, A. Aylott et al., Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients, HIV Clin Trials, vol.15, pp.199-208, 2014.

D. A. Patel, S. J. Snedecor, W. Y. Tang, L. Sudharshan, J. W. Lim et al., 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis, PloS One, vol.9, p.105653, 2014.

S. L. Walmsley, A. Antela, N. Clumeck, D. Duiculescu, A. Eberhard et al., Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection, N Engl J Med, vol.369, pp.1807-1825, 2013.

B. Clotet, J. Feinberg, J. Van-lunzen, K. Antinori, A. Dumitru et al., Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet Lond Engl, vol.383, issue.14, pp.60084-60086, 2014.

F. Raffi, A. Rachlis, H. Stellbrink, W. D. Hardy, C. Torti et al., Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study, Lancet Lond Engl, vol.381, pp.735-778, 2013.

J. J. Eron, B. Clotet, J. Durant, C. Katlama, P. Kumar et al., Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study, J Infect Dis, vol.207, pp.740-748, 2013.

J. Koteff, J. Borland, S. Chen, I. Song, A. Peppercorn et al., A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects, Br J Clin Pharmacol, vol.75, pp.990-996, 2013.

J. Peñafiel, E. De-lazzari, M. Padilla, J. Rojas, A. Gonzalez-cordon et al., Tolerability of integrase inhibitors in a real-life setting, J Antimicrob Chemother, vol.72, pp.1752-1761, 2017.

C. Hoffmann, T. Welz, M. Sabranski, M. Kolb, E. Wolf et al., Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients, HIV Med, vol.18, pp.56-63, 2017.

F. Raffi and M. A. Wainberg, Traitement de l'infection VIH par inhibiteurs d'intégrase : plus d'options, Virologie, vol.17, issue.2, 2013.

J. Zong, J. Borland, F. Jerva, B. Wynne, M. Choukour et al., The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects, J Int AIDS Soc, vol.17, 2014.

I. Song, J. Borland, N. Arya, B. Wynne, and S. Piscitelli, Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects, J Clin Pharmacol, vol.55, pp.490-496, 2015.

R. Verloes, S. Deleu, N. Niemeijer, H. Crauwels, P. Meyvisch et al., Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers, HIV Med, vol.16, pp.477-84, 2015.

A. Wilkin, A. L. Pozniak, J. Morales-ramirez, S. H. Lupo, M. Santoscoy et al., Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial, AIDS Res Hum Retroviruses, vol.28, pp.437-483, 2012.

S. Li, P. Xu, L. Zhang, G. Sun, and Z. Lu, Effectiveness and safety of rilpivirine, a nonnucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV1: a meta-analysis, HIV Clin Trials, vol.15, pp.261-269, 2014.

F. Gutiérrez, X. Fulladosa, G. Barril, and P. Domingo, Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management, AIDS Rev, vol.16, pp.199-212, 2014.

H. Crauwels, R. H. Van, M. Stevens, A. Buelens, S. Vanveggel et al., Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine, AIDS Rev, vol.15, pp.87-101, 2013.

R. D. Cooper, N. Wiebe, N. Smith, P. Keiser, S. Naicker et al., Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.51, pp.496-505, 2010.

J. Young, J. Schäfer, C. A. Fux, H. Furrer, E. Bernasconi et al., Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir, AIDS Lond Engl, vol.26, pp.567-75, 2012.
DOI : 10.1097/qad.0b013e32834f337c

P. Morlat, A. Vivot, M. Vandenhende, F. Dauchy, J. Asselineau et al., Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, PLoS ONE, vol.8, 2004.
URL : https://hal.archives-ouvertes.fr/hal-01101114

A. M. Mills, C. Cohen, E. Dejesus, C. Brinson, S. Williams et al., Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens, HIV Clin Trials, vol.14, pp.216-239, 2013.
DOI : 10.1310/hct1405-216

A. Calmy, C. A. Fux, R. Norris, N. Vallier, C. Delhumeau et al., Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study, J Infect Dis, vol.200, pp.1746-54, 2009.

T. T. Brown, A. C. Ross, N. Storer, D. Labbato, and G. A. Mccomsey, Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens, Antivir Ther, vol.16, 2011.

P. Tebas, W. G. Powderly, S. Claxton, D. Marin, W. Tantisiriwat et al., Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy, AIDS Lond Engl, vol.14, pp.63-67, 2000.

A. L. Moore, A. Vashisht, C. A. Sabin, A. Mocroft, S. Madge et al., Reduced bone mineral density in HIV-positive individuals, AIDS Lond Engl, vol.15, pp.1731-1734, 2001.
DOI : 10.1097/00002030-200109070-00019

M. Núñez, Clinical syndromes and consequences of antiretroviral-related hepatotoxicity, Hepatol Baltim Md, vol.52, pp.1143-55, 2010.

P. Morlat, C. Roussillon, S. Henard, D. Salmon, F. Bonnet et al., Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS Lond Engl, vol.28, pp.1181-91, 2000.

F. J. Palella, M. Fisher, P. Tebas, B. Gazzard, P. Ruane et al., Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants, AIDS Lond Engl, vol.28, pp.335-379, 2014.

E. Martínez, M. Larrousse, J. M. Llibre, F. Gutiérrez, M. Saumoy et al., Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study, AIDS Lond Engl, vol.24, pp.1697-707, 2010.

P. Echeverría, A. Bonjoch, J. Puig, J. Moltó, R. Paredes et al., Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen, Etraswitch Study. PLoS ONE, vol.9, 2014.

B. Mora-peris, V. Watson, J. H. Vera, R. Weston, A. D. Waldman et al., Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapinecontaining combined antiretroviral therapy, J Antimicrob Chemother, vol.69, pp.1642-1649, 2014.

S. L. Letendre, A. M. Mills, K. T. Tashima, D. A. Thomas, S. S. Min et al., ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.59, pp.1032-1039, 2014.

L. Assoumou, C. Charpentier, P. Recordon-pinson, M. Grudé, C. Pallier et al., Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study, J Antimicrob Chemother, vol.72, pp.1769-73, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01984209